长期从事抗肿瘤药物药理（主要研究方向：中西药联用的抗肿瘤机制）和临床药理（主要研究方向：药物临床疗效和安全性）研究工作；近5年来，作为项目负责人获国家自然科学基金面上项目2项、上海市自然基金面上项目1项、崇明区科委科研课题1项，和上海市医院药学科研基金2项；在Clin Microb Infect、Int J Antimicrob
Ag等杂志以第一作者和通讯作者发表SCI收录文章20篇；培养硕士研究生3名。
Main
achievements are involved in pharmacology of anti-cancer drugs (Direction: study on mechanism
of combination of traditional Chinese medicine and western medicine against
cancer), and clinical pharmacology (Direction: assess on efficacy and safety of
drugs); In the recent five years, twenty academic papers have been
published in pharmacy related professional journals at abroad; Research
projects include Natural Science Foundation of China, Natural Science
Foundation of Shanghai, and so on.
（一）发表论文
近 5 年来以第一作者及通讯作者发表论文 22 篇（其中 SCI 收录20 篇）：
1. Xu HB,
Jiang RH, Xiao HP. Clofazimine in the treatment of multidrug-resistant tuberculosis.
Clin Microb Infect 2012; 18: 1104-1110. IF: 4.578
2. Xu HB,
Jiang RH, Li L, Xiao HP. Linezolid in the treatment of MDR-TB: a retrospective
clinical study. Int J Tuberc Lung Dis 2012; 16: 358-363. IF: 2.61
3. Xu HB, Li
L, Fu J, Mao XP, Xu LZ. Reversion of Multidrug Resistance in a Chemoresistant
Human Breast Cancer Cell Line by β-Elemene. Pharmacology 2012; 89:303-312.
IF: 1.603
4. Xu HB,
Chen XZ, Jiang RH, Li L. Chinese herbal medicine in treatment of diabetic peripheral
neuropathy: a systematic review and meta-analysis. J enthopharmacol 2012;
143:701-708. IF: 2.755
5. Xu HB, Xu
LZ, Li L, Fu J, Mao XP. Reversion of P-glycoprotein-mediated multidrug
resistance by guggulsterone in multidrug-resistant human cancer cell lines. Eur
J Pharmacol 2012; 694:39-44. IF: 2.592
6. Liao Y, Zhong MK, Xu
HB ( 通讯作者), Li L. Development and validation
of a risk score for predicting invasive fungal infectious in an intensive care
unit. Pharmazie 2013; 68: 459-464. IF: 1.003
7. Xu HB,
Zheng LP, Li L, Xu LZ, Fu J. Elemene, one ingredient of a Chinese herb, against
malignant tumors: a literature-based meta-analysis. Cancer Invest 2013;
31(2): 156-166. IF: 2.06
8. Chen XZ, Xu HB ( 通讯作者), Xu LZ, Mao XP, Li L. Guggulsterone regulates the function and
expression of P-glycoprotein in rat brain microvessel endothelial cells. Eur
J Pharmacol 2013; 718: 24-29. IF: 2.684
9. Jiang RH, Xu HB (
通讯作者), Li L. Comparative roles of
moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant
tuberculosis: a retrospective study. Int J Antimicrob Ag 2013; 42:
36-41. IF 4.259
2014 年
10. Xu HB,
Jiang RH, Li L. Treatment outcomes for Mycobacterium avium complex: a systematic
review and meta-analysis. Eur J Clin Microbiol Infect Dis 2014; 33(3): 347-358.
IF 2.668
11. Xu HB,
Xu LZ, Mao XP, Fu J. Guggulsterone of Commiphora mukul resin reverses drug
resistance in imatinib-resistant leukemic cells by inhibiting cyclooxygenase-2
and P-glycoprotein. Phytomedicine 2014; 21: 1004-1009. IF 3.126
12. Xu HB,
Shen ZL, Fu J, Xu LZ. Reversal of doxorubicin resistance by guggulsterone of Commiphoramukul
in vivo. Phytomedicine 2014; 21: 1221-1229. IF 3.126
13. 徐陆忠， 徐宏彬（通讯作者），周学琴。GC 法同时测定解热消炎胶囊中 4 种挥发性组分。中成药 2014；36（11）：2319-2322.
14. 苏瑞，李玲， 徐宏彬
（通讯作者）。复方苦参注射液对胃肠道恶性肿瘤辅助治疗的临床观察。中国医院药学杂志 2015；35（4）：322-325。
15. Xu HB,
Huang F, Su R, Shen FM, Lv QZ. Capecitabine plus oxaliplatin (XELOX) compared
with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric
cancer: Meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2015;
71: 589-601. IF 2.71
16. Jiang RH, Xu HB（通讯作者）, Fu J. Outcomes
of Chinese Herb Medicine for the treatment of multidrug-resistant tuberculosis:
a systematic review and meta-analysis. Complement Ther Med 2015; 23:
544-554. IF 1.935
17. Hou LC, Huang F, Xu
HB（通讯作者）. Does celecoxib improve the efficacy of chemotherapy for advanced
non-small cell lung cancer? Br J Clin Pharmacol 2015; 81(1): 23-32. IF
3.83
18. Xu HB,
Shen FM, Lv QZ. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant
human gastric cancer cells by inhibition of cyclooxygenase-2. Eur J Pharmacol
2015; 769: 1-7. IF 2.73
19. Xu HB,
Shen FM, Lv QZ. Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant
gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent
manner. Eur J Pharmacol 2016; 776: 1-8. IF 2.896
20. Xu HB,Yu
J , Xu LZ, Fu J. Regulation of P-glycoprotein efflux activity by Z-guggulsterone
of Commiphora mukul at the blood-brain barrier. J Neurol Sci 2016; 363:
147-152. IF 2.295
21. Xu HB,
Fu J, Huang F, Yu J. Guggulsterone sensitized drug-resistant human hepatocarcinoma
cells to doxorubicin through a Cox-2/P-gp dependent pathway. Eur J Pharmacol
2017; 803: 57-64.IF 2.896
22. Xu HB,
Jiang RH, Sheng HB. Meta-analysis of the effects of Bifidobacterium preparations
for the prevention and treatment of pediatric antibiotic-associated diarrhea in
China. Complement Ther Med 2017; 33: 105-113. IF 2.013
（二）主持课题
近5年来本人作为项目负责人获得资助的科研项目
（其中国自然面上项目2项）：
1. 基于PXR/CAR调控血脑屏障上P-糖蛋白的没药甾酮改善脑胶质瘤化疗疗效的作用研究。 国家自然科学基金面上项目（项目批准号：81774040）2018.1.1-2021.12.31。
2. 利福喷丁对莫西沙星体内药代动力学的影响。崇明区科委“可持续发展科技创新行动计划” 项目（项目编号：CKY2017-20 ），2017.2-2019.2。
3. 没药甾酮抑制环氧酶-2 介导的肿瘤多药耐药细胞 P-糖蛋白表达和抗凋亡作用研究。上海市 科委自然基金面上项目（项目编号：14ZR1432500 ），2014.7.1-2017.6.30。
4. 没药甾酮（guggulsterone)逆转P-糖蛋白介导的肿瘤多药耐药作用及机制研究。国家自然科学基金面上项目（项目批准号：81073104），2011.1.1-2013.12.31。
5. 塞来昔布和顺铂合用逆转胃癌耐药细胞SGC-7901/DDP裸鼠移植瘤作用研究。上海市医院药学科研基金（编号：2014-YY-02-13），上海市药学会，2015.1.1-2015.10.30。
6. 双歧杆菌多联活菌制剂治疗小儿继发性腹泻的meta分析。上海市医院药学科研基金（编号：2014-YY-03-13），上海市药学会，2015.1.1-2015.10.30。
